Investigational anti-obesity drug lorcaserin cleared a major hurdle in gaining FDA approval yesterday when an FDA advisory board approved the drug to be tested further, in consideration for full approval.
Manufactured by Arena pharmaceuticals, the drug will be sold under the brand name Lorqess and works by suppressing a patient’s appetite in order to aide weight loss.
After being rejected by the advisory panel in 2010 citing safety concerns, the makers of lorcaserin were able to supply additional data in support of the drug’s potential benefits outweighing its potential risks.
Lorcaserin joins Qnexa as the second anti-obesity drug to obtain FDA approval this year.
Although the recommendations of the advisory panel are taken into consideration, they do not ensure that a drug will be be granted full FDA approval.
Obesity is a major contributor to diabetes. If you suffer from diabetes, schedule an appointment with an endocrinologist today.